Development of Lateral Flow Immunoassays (LFI) for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)
Closed Pre-Solicitation Posted
- Solicitation number
- W911QY-20-S-0006
- Agency
-
ACC Aberdeen Proving Ground
Army Contracting Command, Department of Defense
- Responses due
- Set-aside
- No set-aside
Opportunity facts
- NAICS code
- 334519 Other Measuring and Controlling Device Manufacturing
- Place of performance
- Frederick MD 21702 USA
Notice details come from SAM.gov. Updated .
About this opportunity
This notice seeks the development of lateral flow immunoassays for detecting SARS-CoV-2. The Defense Biological Product Assurance Office requires easy to use, handheld lateral flow immunoassays for screening nasopharyngeal swab specimens. Respondents must deliver 5,000 assay devices along with clinical buffers and nasal swabs for a third party evaluator by April 24, 2020. Interested parties should contact the contracting officer by April 3, 2020 for additional details.
There is no set-aside designated for this procurement. Respondents must provide reagents, antigens, and positive controls for third party testing and internal use. The contracting officer point of contact is Leo J. Fratis, and responses should be emailed to leo.j.fratis.civ@mail.mil. The procuring agency is the Department of the Army Materiel Command Army Contracting Command located at Aberdeen Proving Ground.
Notice text
3 versions
Update #3 · Latest ·
Defense Biological Product Assurance Office’s (DBPAO) mission is to employ best practices in providing the Department of Defense and its partners with a comprehensive collection of biological products that are: thoroughly characterized, of the highest quality, adaptable and traceable from source to application.
The DBPAO is seeking interested parties to develop Lateral Flow Immunoassays (LFIs) for screening for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). No government funding is provided for developmental efforts of this LFI. The DBPAO seeks the development of an easy to use, hand held LFI for detecting SARS-CoV-2 virus in specimens from infected persons or persons suspected of viral exposure as a screening tool. The LFIs will be used with nasopharyngeal swab specimens, just as existing Polymerase Chain Reaction (PCR) tests are used. The desired LFIs are expected to be conventional assays where the results are manually read by eye. The DBPAO has no specified assay format or specific reagents to be used.
The DBPAO requires a lot of 5000 LFIs devices for testing and evaluation to be delivered to a contracted third party by 24 April 2020. The DBPAO requires potential submitters to provide appropriate clinical buffer and nasal swabs as part of the kit. For third party testing, the submitters also are required to provide for the other reagents and antigens or positive controls used for their internal testing.
Respondents should contact the Contracting Officer cited below by 15 April 2020 for additional details. The Government Contracting Officer for this notice is Mr. Leo Fratis. Responses should be sent by e-mail to: leo.j.fratis.civ@mail.mil.
Update #2 ·
Defense Biological Product Assurance Office’s (DBPAO) mission is to employ best practices in providing the Department of Defense and its partners with a comprehensive collection of biological products that are: thoroughly characterized, of the highest quality, adaptable and traceable from source to application.
The DBPAO is seeking interested parties to develop Lateral Flow Immunoassays (LFIs) for screening for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). No government funding is provided for developmental efforts of this LFI. The DBPAO seeks the development of an easy to use, hand held LFI for detecting SARS-CoV-2 virus in specimens from infected persons or persons suspected of viral exposure as a screening tool. The LFIs will be used with nasopharyngeal swab specimens, just as existing Polymerase Chain Reaction (PCR) tests are used. The desired LFIs are expected to be conventional assays where the results are manually read by eye. The DBPAO has no specified assay format or specific reagents to be used.
The DBPAO requires a lot of 5000 LFIs devices for testing and evaluation to be delivered to a contracted third party by 24 April 2020. The DBPAO requires potential submitters to provide appropriate clinical buffer and nasal swabs as part of the kit. For third party testing, the submitters also are required to provide for the other reagents and antigens or positive controls used for their internal testing.
Respondents should contact the Contracting Officer cited below by 10 April 2020 for additional details. The Government Contracting Officer for this notice is Mr. Leo Fratis. Responses should be sent by e-mail to: leo.j.fratis.civ@mail.mil.
Update #1 ·
Defense Biological Product Assurance Office’s (DBPAO) mission is to employ best practices in providing the Department of Defense and its partners with a comprehensive collection of biological products that are: thoroughly characterized, of the highest quality, adaptable and traceable from source to application.
The DBPAO is seeking interested parties to develop Lateral Flow Immunoassays (LFIs) for screening for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). No government funding is provided for developmental efforts of this LFI. The DBPAO seeks the development of an easy to use, hand held LFI for detecting SARS-CoV-2 virus in specimens from infected persons or persons suspected of viral exposure as a screening tool. The LFIs will be used with nasopharyngeal swab specimens, just as existing Polymerase Chain Reaction (PCR) tests are used. The desired LFIs are expected to be conventional assays where the results are manually read by eye. The DBPAO has no specified assay format or specific reagents to be used.
The DBPAO requires a lot of 5000 LFIs devices for testing and evaluation to be delivered to a contracted third party by 24 April 2020. The DBPAO requires potential submitters to provide appropriate clinical buffer and nasal swabs as part of the kit. For third party testing, the submitters also are required to provide for the other reagents and antigens or positive controls used for their internal testing.
Respondents should contact the Contracting Officer cited below by 3 April 2020 for additional details. The Government Contracting Officer for this notice is Mr. Leo Fratis. Responses should be sent by e-mail to: leo.j.fratis.civ@mail.mil.
Similar open opportunities
| Opportunity | Agency | Set-aside | Responses due |
|---|---|---|---|
| W912CH-26-R-0072 for HAND HELD ASSAY, NSN:6665-01-568-0616 | Department of the Army | No set-aside | |
| Test kit, human immuno | Medical Supply Chain | No set-aside | |
| Request for Information (RFI) Enhanced Maritime Biological Detection (EMBD) Identification Subsystem (IDS) | ACC Aberdeen Proving Ground | No set-aside | |
| Purchase of Rapid Syndromic Molecular Testing Reagents for Seattle VAMC | Veterans Integrated Service Network 20 | No set-aside |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar opportunities
- Ask GovTribe AI about this opportunity